A Deep Dive into Liver Cancer Diagnostics Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034

"Which drivers are expected to have the greatest impact on the over the liver cancer diagnostics market's growth?
The increasing incidence of liver cancer is projected to stimulate the expansion of the liver cancer diagnostics market. Liver cancer is a fatal ailment resulting from uncontrolled growth and multiplication of liver cells. Diagnostic tests for liver cancer aim at identifying whether cancer cells are proliferating within or around the liver after the primary diagnosis of liver carcinoma. Consequently, the escalating incidence of liver cancer fuels the liver cancer diagnostics market's growth. For example, the January 2023 report, Cancer Facts & Figures 2023, from the American Cancer Society, a voluntary health organization based in the US, indicates that the count of new liver and intrahepatic bile duct cancer cases among women rose from 12,640 in 2020 to 13,230 in 2023 in the US alone. Moreover, it is estimated that in 2023, about 41,210 fresh cases of liver cancer will be identified in the US, with an expected fatality count of 29,380. Hence, the growing incidence of liver cancer propels the development of the liver cancer diagnostics market.

Get Your Liver Cancer Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

What is the future CAGR of the liver cancer diagnostics market, and how will it impact industry expansion?
In recent times, the market size for liver cancer diagnostics has seen considerable growth. It is projected to increase from $9.69 billion in 2024 to $10.4 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. The historical growth can be linked to advancement in biopsy strategies and histopathology, the progression of biomarker detection, the enhancement of screening programs, the development in genetic testing, and betterment in liver imaging techniques.

The market for liver cancer diagnostics is projected to experience significant expansion in the coming years, reaching a valuation of ""$13.86 billion in 2029 with a CAGR of 7.4%. The predicted growth during this period is due to factors such as regulatory adjustments and standardization, the increasing relevance of imaging modalities, the emergence of next-generation sequencing, wider screening programs and increased awareness, and a surge in demand for biomarker-based tests. Key trends for this period are anticipated to be a growth in occurrence and prevalence, advancements in imaging technologies, a shifted emphasis towards non-invasive diagnostics, precision and personalized diagnostics, and the incorporation of Artificial Intelligence (AI).

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What are the most significant trends transforming the liver cancer diagnostics market today?
Leading corporations in the liver cancer diagnostics market are pioneering the creation of sophisticated biomarker-based assays and algorithms which enhance diagnostic precision and promote early identification of the disease. These diagnostic innovations make use of unique biological markers to accurately pinpoint diseases, thus improving the efficiency and effectiveness of diagnosis. In November 2023, Roche Diagnostics, a biotech firm located in the US, rolled out the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay detects an increase in PIVKA-II biomarker levels, which is linked with hepatocellular carcinoma (HCC), thereby aiding in the early detection of liver cancer in patients at a high risk. The Elecsys GAAD algorithm, on the other hand, amalgamates various diagnostic markers such as PIVKA-II and AFP, which boosts diagnostic accuracy and simplifies decision-making in the diagnosis of liver cancer.

Which key market segments comprise the liver cancer diagnostics market and drive its revenue growth?
The liver cancer diagnostics market covered in this report is segmented -

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10481

What regions are at the forefront of liver cancer diagnostics market expansion?
North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the liver cancer diagnostics market?
Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What Is Covered In The Liver Cancer Diagnostics Global Market Report?

• Market Size Forecast: Examine the liver cancer diagnostics market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the liver cancer diagnostics market for a structured understanding.
• Key Players Overview: Analyze major players in the liver cancer diagnostics market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the liver cancer diagnostics market.
• Segment Contributions: Evaluate how different segments drive overall growth in the liver cancer diagnostics market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the liver cancer diagnostics market.
• Industry Challenges: Identify potential risks and obstacles affecting the liver cancer diagnostics market.
• Competitive Landscape: Review strategic developments in the liver cancer diagnostics market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead

This release was published on openPR.